TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
Background. We investigated the efficacy of TILs and anti-PD1 combination therapy in patients with metastatic cervical cancer with low MSI expression and PDL1-negative. Methods. A total of 80 patients were put on TILs and anti-PD1 combination therapy, and the progression-free survival time (PFS) and...
Saved in:
Main Authors: | Huanhuan Yin, Wei Guo, Xiangling Sun, Ruili Li, Cuihua Feng, Yujie Tan |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2020/8345235 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
by: Rangarirai Makuku, et al.
Published: (2021-01-01) -
MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers
by: Ibrahim Halil Erdogdu
Published: (2019-01-01) -
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
by: Sandip P. Patel, et al.
Published: (2025-01-01) -
WNT11 Promotes immune evasion and resistance to Anti-PD-1 therapy in liver metastasis
by: Weiliang Jiang, et al.
Published: (2025-02-01) -
TYRO3 blockade enhances anti-PD-1 therapy response by modulating expression of CCN1 in tumor microenvironment
by: Miso Park, et al.
Published: (2023-01-01)